USPTO serial 87836345
CURA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- POLLACK, ALISON FRIEDBERG
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CURA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rhett V. Barney
Rhett V. Barney LEE & HAYES, PC601 WEST RIVERSIDESUITE 1400SPOKANE, WA 99201Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Computer software for use in medical diagnostics using medical image analysis, medical records analysis, and bioinformatics analysis supporting clinicians and researchers in fields of radiology, cardiology, oncology, pulmonology, neurology, hematology, endocrinology, otolaryngology, gynecology, obstetrics, urology, orthopedics, ophthalmology, pathology, pediatrics, physical medicine, surgery, emergency medicine, medical genetics and genomics, dermatology, family medicine, internal medicine, colorectal medicine, psychiatry, allergy and immunology, and preventive medicine; computer software for the analysis of medical data, namely, genomics data, for use in identifying and predicting actionable biomarkers, neoantigens, and molecular data for developing paired diagnostics and therapeutics in the fields of radiology, cardiology, oncology, pulmonology, neurology, hematology, endocrinology, otolaryngology, gynecology, obstetrics, urology, orthopedics, ophthalmology, pathology, pediatrics, physical medicine, surgery, emergency medicine, medical genetics and genomics, dermatology, family medicine, internal medicine, colorectal medicine, psychiatry, allergy and immunology, and preventive medicine; computer software for executing preconfigured non-field specific machine learning and deep learning algorithms and processes for the purposes of uploading and managing data for the training of preconfigured data models implemented on a hosted software platform utilizing said machine learning and deep learning processes and for utilizing said trained data models for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes; computer software for conducting natural language processing on medical records to transform unstructured data into structured data supporting clinical and research use; computer software for detecting and predicting neoantigens and peptides for immunotherapy development | ACTIVE | — |
| 042 | Providing software as a service (SaaS) services featuring software for use in medical diagnostics using medical image analysis, medical records analysis, and bioinformatics analysis supporting clinicians and researchers in fields of radiology, cardiology, oncology, pulmonology, neurology, hematology, endocrinology, otolaryngology, gynecology, obstetrics, urology, orthopedics, ophthalmology, pathology, pediatrics, physical medicine, surgery, emergency medicine, medical genetics and genomics, dermatology, family medicine, internal medicine, colorectal medicine, psychiatry, allergy and immunology, and preventive medicine; providing software as a service (SaaS) services featuring software for the analysis of medical data, namely, genomics data for use in identifying and predicting actionable biomarkers, neoantigens, and molecular data for developing paired diagnostics and therapeutics in the fields of radiology, cardiology, oncology, pulmonology, neurology, hematology, endocrinology, otolaryngology, gynecology, obstetrics, urology, orthopedics, ophthalmology, pathology, pediatrics, physical medicine, surgery, emergency medicine, medical genetics and genomics, dermatology, family medicine, internal medicine, colorectal medicine, psychiatry, allergy and immunology, and preventive medicine; providing software as a service (SaaS) services featuring software for executing preconfigured non-field specific machine learning and deep learning algorithms and processes for the purposes of uploading and managing data for the training of preconfigured data models implemented on a hosted software platform utilizing said machine learning and deep learning processes and for utilizing said trained data models for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes; providing software as a service (SaaS) services featuring software for conducting natural language processing on medical records to transform unstructured data into structured data supporting clinical and research use; providing software as a service (SaaS) services featuring software for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes, in particular for detecting and predicting significance of neoantigens and peptides on cells relevant to immunotherapy development | ACTIVE | — |
| 044 | Performing medical testing for diagnostic purposes, in particular for diagnostic imaging, including x- rays, computed tomography, magnetic resonance imaging (MRI) and other modalities; performing medical testing on tissue samples and body fluids for the detection of genetic and genomic information pertaining to human disease for medical diagnostic or treatment purposes; providing medical information to others in the field of human disease, human medical conditions, medical diagnostic testing services and medical testing for diagnostic or treatment purposes of radiology, cardiology, oncology, pulmonology, neurology, hematology, endocrinology, otolaryngology, gynecology, obstetrics, urology, orthopedics, ophthalmology, pathology, pediatrics, physical medicine, surgery, emergency medicine, medical genetics, dermatology, family medicine, internal medicine, colorectal medicine, psychiatry, allergy and immunology, and preventive medicine | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CuraCloud Corporation
- Other trademarks owned by KEYAMED NA INC.
- Other trademarks owned by CuraCloud Corporation
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CURA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 3, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 3, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 6, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 5, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Dec 2, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Dec 2, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 20, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 18, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| May 18, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| May 18, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 2, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 30, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Nov 30, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Nov 30, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 26, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 25, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| May 25, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 19, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 19, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 24, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Dec 4, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 2, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 2, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 2, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 2, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 7, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 7, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 18, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 18, 2020 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Feb 6, 2020 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 3, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 31, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 30, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 30, 2020 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 3, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 3, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 3, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 18, 2019 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jun 6, 2019 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jun 4, 2019 | ALIE | ASSIGNED TO LIE | — |
| Nov 2, 2018 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 2, 2018 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 2, 2018 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 24, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 23, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 23, 2018 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Aug 15, 2018 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Aug 15, 2018 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Aug 15, 2018 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 14, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 13, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 13, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 2, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 2, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 2, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 26, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 22, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 19, 2018 | NWAP | NEW APPLICATION ENTERED | — |